Aptose Biosciences to Acquire Allarity Therapeutics

TL;DR

APTO buying ALLR, deal expected Q2 2024.

AI Summary

Allarity Therapeutics, Inc. announced on April 4, 2024, that it has entered into a definitive agreement to be acquired by Aptose Biosciences Inc. The transaction is expected to close in the second quarter of 2024. This acquisition aims to combine Allarity's pipeline with Aptose's existing assets.

Why It Matters

This acquisition could lead to the consolidation of drug development efforts in the oncology space, potentially impacting the future of both companies' pipelines and investor portfolios.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including shareholder approval, which introduces uncertainty regarding its completion.

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Company filing the 8-K and being acquired
• Aptose Biosciences Inc. (company) — Acquiring company
• April 4, 2024 (date) — Date of the definitive agreement
• second quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar

Filing Documents

• ea020336201-8k_allarity.htm (8-K) — 25KB
• ea020336201ex99-1_allarity.htm (EX-99.1) — 18KB
• image_001.jpg (GRAPHIC) — 3KB
• image_004.jpg (GRAPHIC) — 3KB
• image_003.jpg (GRAPHIC) — 3KB
• image_002.jpg (GRAPHIC) — 3KB
• 0001213900-24-030624.txt ( ) — 237KB
• allr-20240404.xsd (EX-101.SCH) — 3KB
• allr-20240404_lab.xml (EX-101.LAB) — 33KB
• allr-20240404_pre.xml (EX-101.PRE) — 22KB
• ea020336201-8k_allarity_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 4, 2024, Allarity Therapeutics, Inc., a Delaware corporation ("we," "our," or the "Company"), issued a press release announcing the approval by our Board of Directors of a Fifth Certificate of Amendment to Certificate of Incorporation to effect a reverse stock split of Company common stock, par value $0.0001 per share (the "Common Stock"). As of 9:30 a.m. (Eastern Time) on April 9, 2024, every 20 shares of issued and outstanding Common Stock will be automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933, as amended or the Exchange Act. By furnishing this information on this Current Report on Form 8-K, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated April 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: April 5, 2024 2

View Full Filing

View this 8-K filing on SEC EDGAR